Press release
Peptide Therapeutics Market (2026) | GLP-1 Drugs, FDA Approvals 2026, Peptide Drugs, R&D Expansion, Global Growth 2026 | Top Companies 2026 - Ever Neuro Pharma GmbH, Novo Nordisk AS., Pfizer Inc
Peptide Therapeutics Market Size 2026
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/peptide-therapeutics-market?kb
Telehealth & Innovation Drive Peptide Market Expansion
✦ FDA policy changes could unlock new revenue streams for telehealth leaders like Hims & Hers Health and Ro.
✦ Peptide demand is surging alongside GLP-1 therapies, with over 1 in 8 Americans using metabolic treatments.
✦ U.S. imports of peptide-related compounds reached US$328 million in the first nine months of 2025, nearly doubling year-over-year.
✦ Integration of advanced technologies like quantum computing is accelerating peptide drug discovery and precision therapeutics.
✦ Growing investor interest positions peptides as the next major consumer health and biotech category.
List of Key Players 2026:
Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, and Novo Nordisk AS.
Regulatory Shift Unlocks New Growth in Peptide Therapeutics
➠ The U.S. Food and Drug Administration is expected to reverse restrictions on 14 injectable peptides, reopening opportunities for compounding pharmacies.
➠ The earlier 2023 ban cited safety concerns including immunogenicity, toxicity, and impurity risks.
➠ Rising demand for wellness, anti-aging, and sports medicine applications is accelerating market momentum.
➠ The policy shift could expand access through regulated channels, reducing reliance on unverified imports.
Ready to scale in the Peptide Therapeutics Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/peptide-therapeutics-market?kb
Partner Identification
✓Increase Your Customer Base by 3X using our Partner Identification tool
✓Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
✓Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
✓Prioritize partners by strategic fit rather than general capability.
Growth Forecast Projected 2026:
The Global Peptide Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Key Developments 2025-2026:
✅ February 2026: Market players accelerated development of next-generation peptide drugs with enhanced stability, bioavailability, and targeted delivery for oncology and metabolic disorders.
✅ January 2026: Pharmaceutical companies expanded clinical pipelines focusing on peptide-based therapies for diabetes, obesity, and rare diseases, supported by increasing investment in biologics.
✅ December 2025: Advancements in peptide synthesis technologies improved scalability and reduced production costs, enabling broader commercialization of peptide therapeutics.
✅ November 2025: Strategic collaborations and licensing agreements increased between biotech firms and pharmaceutical companies to strengthen peptide drug development capabilities.
✅ October 2025: Growing regulatory approvals for peptide-based drugs accelerated market adoption, particularly in chronic disease management and hormone-related therapies.
How Our Market Research Process Works:
The global Peptide Therapeutics Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Peptide Therapeutics ecosystem.
United States: Recent Industry Developments
✅ March 2026: Eli Lilly and Company advanced clinical trials for next-generation GLP-1 peptide therapeutics targeting obesity and type 2 diabetes.
✅ February 2026: Amgen Inc. expanded its peptide drug pipeline with novel candidates focused on oncology and metabolic disorders.
✅ January 2026: Pfizer Inc. strengthened peptide manufacturing capabilities to support large-scale production of innovative biologics.
✅ December 2025: Merck & Co., Inc. increased R&D investments in peptide-based therapeutics for cancer and immunological diseases.
Recent Mergers & Acquisitions (M & A) 2025-2026:
• March 2026 - Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8B, strengthening its peptide-linked CNS pipeline including orexin-targeting therapies
• February 2026 - Novartis signed a licensing deal with Unnatural Products worth up to $1.7B to develop macrocyclic peptide therapeutics for cardiovascular diseases
• February 2026 - Novo Nordisk entered a partnership with Vivtex (up to $2.1B) to advance oral delivery technologies for peptide and biologic drugs in obesity and diabetes
• January 2026 - Sanofi partnered with Earendil to discover novel immunology therapies, including peptide-based targets, using AI-driven drug discovery platforms
Request Strategic Market Customization: https://datamintelligence.com/customize/peptide-therapeutics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company Limited accelerated development of peptide therapeutics for rare diseases and gastrointestinal disorders.
✅ February 2026: Astellas Pharma Inc. progressed peptide drug candidates targeting oncology and precision medicine applications.
✅ January 2026: Daiichi Sankyo Company, Limited expanded research in peptide-drug conjugates (PDCs) for targeted cancer therapies.
✅ December 2025: Shionogi & Co., Ltd. enhanced collaborations to develop peptide-based anti-infective therapies.
Major Focused Key Segmentations 2026:
By Type: Patented, Generic
By Application: Cancer, Cardiovascular Diseases, Metabolic Diseases, Central Nervous System Disorders, Respiratory Diseases, Infectious Diseases
By Route of Administration: Oral Route, Parenteral Route
By Technology: Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Phase Peptide Synthesis (HPPS)
Latest FDA Approvals - Peptide Therapeutics
✔ March 2026: Johnson & Johnson received FDA approval for ICOTYDETM (icotrokinra), the first oral IL-23 receptor-targeting peptide for plaque psoriasis, marking a breakthrough in oral peptide therapies.
✔ 2025: The FDA approved one novel peptide-based drug among 46 new drugs, highlighting continued but selective growth in peptide therapeutics.
✔ 2025: Approval of peptide-linked antibody-drug conjugates (ADCs) and advanced TIDES therapies expanded the role of peptides in targeted drug delivery
Regional Growth Analysis for Market:
⇥ North America: Leads the market driven by strong biopharmaceutical innovation, advanced healthcare infrastructure, and high adoption of peptide-based drugs.
⇥ Asia-Pacific (including Japan): Rapidly expanding due to growing pharmaceutical manufacturing, increasing clinical research, and rising demand for targeted therapies.
⇥ Europe: Significant growth supported by regulatory support, increasing R&D investments, and strong presence of biotech companies.
⇥ Middle East & Africa: Emerging market driven by improving healthcare access, rising awareness, and gradual adoption of advanced therapeutics.
Latest News - Peptide Therapeutics
» April 2026: FDA approved orforglipron (Eli Lilly), a once-daily oral GLP-1 therapy, intensifying competition in obesity and metabolic peptide drugs.
» March 2026: The FDA is considering lifting restrictions on several compounded peptides, signaling potential regulatory easing for peptide-based therapies.
» 2026 Outlook: Multiple next-generation peptide drugs (e.g., dual GLP-1/GIP therapies) are under FDA review, indicating strong pipeline momentum in metabolic and chronic disease treatmen
We Provide Benefits of the Report:
Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.
Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.
Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.
Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.
Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.
Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.
Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.
Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.
Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.
Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=peptide-therapeutics-market?kb
FAQ
Q: How rapidly will the Market expanding?
A: The Peptide Therapeutics market is projected to grow at a CAGR of 7.8% between 2024 and 2031.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptide Therapeutics Market (2026) | GLP-1 Drugs, FDA Approvals 2026, Peptide Drugs, R&D Expansion, Global Growth 2026 | Top Companies 2026 - Ever Neuro Pharma GmbH, Novo Nordisk AS., Pfizer Inc here
News-ID: 4452752 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Critical Limb Ischemia Treatment Market to Reach US$ 13.13 Billion by 2032 at 7. …
The global Critical Limb Ischemia (CLI) Treatment Market reached US$6.02 billion in 2024 and is expected to reach US$13.13 billion by 2032, growing at a CAGR of 7.90% during the forecast period of 2025 to 2032. The market is expanding steadily due to the increasing prevalence of peripheral artery disease (PAD) and the rising need for effective treatment solutions to prevent limb loss and improve patient outcomes.
Critical Limb Ischemia (CLI)…
Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North Am …
The global biopsy devices market reached US$2.68 billion in 2025 and is expected to reach US$6.85 billion by 2033, growing at a CAGR of 10.15% during the forecast period 2026 to 2033. The market is expanding steadily as the demand for early and accurate disease diagnosis, particularly for cancer, continues to rise globally.
Market growth is driven by the increasing prevalence of cancer and other chronic diseases, growing awareness about early…
Biobanking Services Market Set for Steady Growth to US$ 81.68 Billion by 2033, L …
The global Biobanking Services Market reached US$ 48.56 Billion in 2023, with a rise of US$ 51.00 Billion in 2024 and is expected to reach US$ 81.68 Billion by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033.
The market is steadily expanding as healthcare providers, research institutions, and biotech firms prioritize advanced sample storage, automated retrieval systems, and AI-integrated data management, driven by surging demand for precision…
Cool Roofs Market (2026) | Aluminum Roof Coatings, Roofing Membranes, Reflective …
DataM Intelligence has released a new research report titled "Cool Roofs Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms…
More Releases for Peptide
ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in H …
ShiLai Peptide's CEO, Luo Binhua, said the investment reflects the company's commitment to a "new science model" that integrates research-driven development, controlled production, and specialized customer support.
ShiLai Peptide [https://retatrutidesupplier.com/], a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory in Hangzhou. The facility is designed to meet world-class GMP standards, aiming to strengthen ShiLai's global supply of…
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
